Telbivudine

Telbivudine is an antiviral drug used in the treatment of hepatitis B infection. It is marketed by Swiss pharmaceutical company Novartis under the trade names Sebivo (European Union) and Tyzeka (United States). Clinical trials have shown it to be significantly more effective than lamivudine or adefovir, and less likely to cause resistance.[1][2][3] However, HBV signature resistance mutation M204I (a change from methionine to isoleucine at position 204 in the reverse transcriptase domain of the hepatitis B polymerase) or L180M+M204V have been associated with Telbivudine resistance.[4]

Telbivudine
Clinical data
Trade namesTyzeka, Sebivo
Other names1-(2-deoxy-β-L-ribofuranosyl)-5-methyluracil
β-L-2-deoxythymidine
β-L-thymidine (LdT)
1-[(2S,4R,5S)-4-hydroxy-5-hydroxymethyltetrahydrofuran-2-yl]-5-methyl-1H-pyrimidine-2,4-dione
AHFS/Drugs.comMonograph
MedlinePlusa607045
License data
Pregnancy
category
  • AU: B1
Routes of
administration		By mouth
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
  • EU: Rx-only
Pharmacokinetic data
Protein bindingLow (3.3% in vitro)
MetabolismNil
Elimination half-life40 to 49 hours (terminal phase)
ExcretionKidney
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.125.511
Chemical and physical data
FormulaC10H14N2O5
Molar mass242.231 g·mol−1
3D model (JSmol)
 NY (what is this?)  (verify)

Telbivudine is a synthetic thymidine β-L-nucleoside analogue; it is the L-isomer of thymidine. Telbivudine impairs hepatitis B virus (HBV) DNA replication by leading to chain termination. It differs from the natural nucleotide only with respect to the location of the sugar and base moieties, taking on an levorotatory configuration versus a dextrorotatory configuration as do the natural deoxynucleosides.[5] It is taken orally in a dose of 600 mg once daily with or without food.

In 2016, Novartis posted a discontinuation notice for Tyzeka.[6][7]

References
  1. Lai CL, Leung N, Teo EK, et al. (2005). "A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B". Gastroenterology. 129 (2): 528–36. doi:10.1016/j.gastro.2005.05.053. PMID 16083710.
  2. Lai CL, Gane E, Liaw YF, et al. (2007). "Telbivudine versus lamivudine in patients with chronic hepatitis B". N Engl J Med. 357 (25): 2576–88. doi:10.1056/NEJMoa066422. hdl:10722/57525. PMID 18094378.
  3. Chan HL, Heathcote EJ, Marcellin P, et al. (4 December 2007). "Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial". Ann Intern Med. 147 (11): 745–54. doi:10.7326/0003-4819-147-11-200712040-00183. PMID 17909201.
  4. Osborn MK (2009). "Safety and efficacy of telbivudine for the treatment of chronic hepatitis B". Ther Clin Risk Manag. 5: 789–98. doi:10.2147/tcrm.s5318. PMC 2762437. PMID 19851526.
  5. Osborn MK. "Safety and efficacy of telbivudine for the treatment of chronic hepatitis B". Ther Clin Risk Manag. 5: 789–98. PMC 2762437. PMID 19851526.
  6. "HBV drug Tyzeka discontinued". www.healio.com. Retrieved 2021-01-11.
  7. "FDA: Hepatitis B Drug Discontinued". MPR. 2016-10-05. Retrieved 2021-01-11.
  • "Telbivudine". Drug Information Portal. U.S. National Library of Medicine.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.